Celator Pharmaceuticals, 303 B College Road East, Princeton 08540; 609-243-0123; fax, 609-243-0202. Scott Jackson, CEO. www.celatorpharma.com.
Celator Pharmaceuticals has raised $39 million for research into a leukemia drug. The money will help fund a Phase 3 clinical study of CPX-351, an injection for patients aged 60 to 75 with acute myeloid leukemia.
The 300-patient randomized controlled study will compare the survival rates of patients who take new drug against those who are given conventional drug therapy.
The financing, raised by a private placement of common stock, was led by Valence Life Sciences.
Laser Energetics Inc., 3535 Quakerbridge Road, Suite 700, Mercerville 08619; 609-587-8250; fax, 609-587-9315. Robert D. Battis, CEO. www.laserenergetics.com.
Laser Energetics of Quakerbridge Road in Mercerville announced an order to sell non-lethal laser weapons to Saudi Arabian special forces.
The company’s Dazer Guardian system is advertised to temporarily blind people with a green light, without permanently damaging their eyes, from point-blank range out to a kilometer away. The company will also train commandos how to use the lasers in hopes of following up with a much larger contract with the Saudi military and government.
Laser dazzlers manufactured by Laser Energetics and other companies are commonly used by military and security forces around the world to incapacitate opponents’ eyesight or sensors. Laser Energetics has also sold its Dazer system to the Israeli Department of Corrections and 13 other countries.
